Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093050 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers
A Phase 1 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04093050: Completed Phase 1 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT04093050 is a Phase 1 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04093050, a Phase 1 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Open-label Phase I pharmacokinetic (PK) study of Vasostrict® (vasopressin injection, USP) in healthy volunteers.
Interventions
- DRUG Vasostrict Injectable Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-10-10 |
| Est. Completion | 2021-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04093050
The ClinicalTrials.gov registry entry for NCT04093050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vasostrict Injectable Product is the first listed.
NCT04093050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04093050 about?
NCT04093050 is a clinical study titled "Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers". Open-label Phase I pharmacokinetic (PK) study of Vasostrict® (vasopressin injection, USP) in healthy volunteers.
What is the current status of trial NCT04093050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-10-10. Estimated completion is 2021-04-11.
What interventions are being tested in trial NCT04093050?
The interventions under investigation include: Vasostrict Injectable Product (DRUG).
Who is sponsoring clinical trial NCT04093050?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.